{
  "abstract": "Introduction To evaluate current treatment patterns for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and identify factors influencing therapy initiation, switching, discontinuation, and combination strategies.Material and Methods SSc-ILD patients started on immunesuppresive and/or anti-fibrotic therapies from the EUSTAR database in the contemporary cohort (>=2017) were identified. Treatment regimens, including monotherapy, combination therapies, switchs and suspensions as well as factors influencing treatment decisions, were analyzed using multivariable logistic regression.Results Among 277 patients, 377 mycophenolate mofetil-based regimens, 186 methotrexate-based regimens, 257 rituximab-based regimens and 122 tocilizumab-based regimens were identified, see figure 1. 14% of regimens were switched from one drug to another and 24% were stopped. We identified that shorter disease duration was significantly associated with IST and antifibrotic therapy initiation at the first evaluation (OR 0.991, 95% CI 0.987–0.996, p <0.001). Additionally, the presence of concomitant myositis was strongly linked to IST and antifibrotic therapy initiation (OR 9.934, 95% CI 1.936-51.764, p = 0.006). The likelihood of switching treatments was significantly higher in patients with a higher mRSS (OR 1.031, 95% CI 1.002 – 1.062, p = 0.035) and in patients with arthritis (OR 3.034, 95% CI 1.551 – 5.936, p = 0.001). No clinical feature was found to be significantly associated with treatment discontinuation. Throughout the study period, the use of combination therapy was associated with younger age (OR 0.968, 95% CI 0.953 – 0.985, p <0.001), higher dyspnea class (OR 1.557, 95% CI 1.189 – 2.039, p = 0.001), and inflammatory arthritis (OR 2.560, 95% CI 1.354 – 4.840, p = 0.004).Conclusions In the contemporary cohort, MMF is the cornerstone of therapy, often used in combination (>50%). Clinical factors such as disease duration, myositis, and lung function impairment significantly influence treatment choices, offering valuable insights for future clinical trial design and personalized patient management.Abstract OC.01 Figure 1Combination therapies in patients treated in year ≥ 2017 according to the DMARD-based regimen (panel A mycophenolate mofetil-based regimens; panel B methotrexate-based regimens; panel C rituximab-based regimens and panel D tocilizumab-based regimens)",
  "authors": [
    {
      "affiliations": [
        "Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Ra, Milan, Italy"
      ],
      "name": "Corrado Campochiaro"
    },
    {
      "affiliations": [
        "Department of Rheumatology, University of Bordeaux, France, Bordeaux, France"
      ],
      "name": "Marie-Elise Truchetet"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, The Netherlands"
      ],
      "name": "Madelon Vonk"
    },
    {
      "affiliations": [
        "Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Ra, Milan, Italy"
      ],
      "name": "Giacomo De Luca"
    },
    {
      "affiliations": [
        "Department of Rheumatology, University of Naples Federico II, Italy, Naples, Italy"
      ],
      "name": "Giovanna Cuomo"
    },
    {
      "affiliations": [
        "Department of Internal Medicine, Russian Academy of Sciences, Moscow, Russia, Moscow, Russia"
      ],
      "name": "Lidia P Ananieva"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Lille University Hospital, France, Lille, France"
      ],
      "name": "Eric Hachulla"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Ghent University Hospital, Belgium, Ghent, Belgium"
      ],
      "name": "Vanessa Smith"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Bucharest University Emergency Hospital, Romania, Bucharest, Romania"
      ],
      "name": "Ana Maria Gheorghiu"
    },
    {
      "affiliations": [
        "Department of Internal Medicine, Charles University, Prague, Czech Republic, Prague, CZECH Republic"
      ],
      "name": "Radim Becvar"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, Madrid, Spain"
      ],
      "name": "Patricia Carreira"
    },
    {
      "affiliations": [
        "Department of Dermatology, University Hospital of Cologne, Germany, Cologne, Germany"
      ],
      "name": "Nicolas Hunzelmann"
    },
    {
      "affiliations": [
        "David Geffen School of Medicine, University of California, Los Angeles, USA, Los Angeles, USA"
      ],
      "name": "Daniel E Furst"
    },
    {
      "affiliations": [
        "Rheumatology Unit, Vall d Hebron University Hospital, Barcelona, Spain, Barcelona, Spain"
      ],
      "name": "Vera Ortiz-Santamaria"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, United Kingdom, Leeds, United Kingdom"
      ],
      "name": "Francesco Del Galdo"
    },
    {
      "affiliations": [
        "Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Ra, Milan, Italy"
      ],
      "name": "Marco Matucci Cerinic"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway",
        "Department of Rheumatology, University Hospital Zurich, Zurich, Norway, Zurich, Switzerland"
      ],
      "name": "Anna Maria Hoffmann Vold"
    }
  ],
  "title": "OC.01 Contemporary treatment patterns and clinical determinants of therapy choices in systemic sclerosis-associated interstitial lung disease: insights from the eustar database",
  "uid": "32c054d5-a160-5e48-a253-affe01b301b3"
}